A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Study ID
NCT02571036

Study type
Interventional

Study phase
Phase 1

Study status
Completed

Trial Acronym

Trial Summary

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

More informations

Trial Starting Date

Nov 30,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

282